JP2025503215A5 - - Google Patents

Info

Publication number
JP2025503215A5
JP2025503215A5 JP2024544710A JP2024544710A JP2025503215A5 JP 2025503215 A5 JP2025503215 A5 JP 2025503215A5 JP 2024544710 A JP2024544710 A JP 2024544710A JP 2024544710 A JP2024544710 A JP 2024544710A JP 2025503215 A5 JP2025503215 A5 JP 2025503215A5
Authority
JP
Japan
Prior art keywords
mammal
radiopharmaceutical
combination according
group
ddri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2023/050108 external-priority patent/WO2023141717A1/en
Publication of JP2025503215A publication Critical patent/JP2025503215A/ja
Publication of JP2025503215A5 publication Critical patent/JP2025503215A5/ja
Pending legal-status Critical Current

Links

JP2024544710A 2022-01-28 2023-01-27 Ntsr1標的化放射性医薬品およびdna損傷応答阻害剤併用療法 Pending JP2025503215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263304178P 2022-01-28 2022-01-28
US63/304,178 2022-01-28
PCT/CA2023/050108 WO2023141717A1 (en) 2022-01-28 2023-01-27 Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy

Publications (2)

Publication Number Publication Date
JP2025503215A JP2025503215A (ja) 2025-01-30
JP2025503215A5 true JP2025503215A5 (cg-RX-API-DMAC10.html) 2026-02-04

Family

ID=87469883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544710A Pending JP2025503215A (ja) 2022-01-28 2023-01-27 Ntsr1標的化放射性医薬品およびdna損傷応答阻害剤併用療法

Country Status (12)

Country Link
US (1) US20250177581A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469092A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025503215A (cg-RX-API-DMAC10.html)
KR (1) KR20240142499A (cg-RX-API-DMAC10.html)
CN (1) CN119136846A (cg-RX-API-DMAC10.html)
AR (1) AR128382A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023211719A1 (cg-RX-API-DMAC10.html)
CA (1) CA3249955A1 (cg-RX-API-DMAC10.html)
IL (1) IL314530A (cg-RX-API-DMAC10.html)
MX (1) MX2024009312A (cg-RX-API-DMAC10.html)
TW (1) TW202337451A (cg-RX-API-DMAC10.html)
WO (1) WO2023141717A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4355325A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION OF A NEUROTENSIN RECEPTOR-BINDING COMPOUND AND FOLFIRINOX

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2478695B1 (es) * 2012-12-20 2015-04-28 Servicio Andaluz De Salud Dispositivo para inducir hipotermia terapéutica
KR20210099073A (ko) * 2018-12-03 2021-08-11 퓨전 파마슈티칼즈 인크. 방사성면역접합체와 체크포인트 억제제의 조합 요법

Similar Documents

Publication Publication Date Title
Poty et al. α-emitters for radiotherapy: from basic radiochemistry to clinical studies—part 1
Pallares et al. Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
Kratochwil et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer
Wild et al. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)
Poty et al. α-emitters for radiotherapy: from basic radiochemistry to clinical studies—part 2
Kelly et al. Albumin-binding PSMA ligands: implications for expanding the therapeutic window
Lin et al. Peptide binder to glypican-3 as a theranostic agent for hepatocellular carcinoma
Benešová et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer
Miao et al. Therapeutic efficacy of a 188Re-labeled α-melanocyte–stimulating hormone peptide analog in murine and human melanoma-bearing mouse models
CN110612126B (zh) 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体
Kasbollah et al. Review on production of 89Zr in a medical cyclotron for PET radiopharmaceuticals
Béhé et al. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys
Maguire et al. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer
JP2022511471A5 (cg-RX-API-DMAC10.html)
JP2022516170A5 (cg-RX-API-DMAC10.html)
Feng et al. Effective treatment of human breast carcinoma xenografts with single-dose 211At-labeled anti-HER2 single-domain antibody fragment
TWI878344B (zh) 放射性標記grpr拮抗劑之方法及其套組
Sanad et al. Radiodiagnosis of peptic ulcer with technetium-99 m-labeled esomeprazole
Bobba et al. Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5
McInnes et al. Therapeutic efficacy of a bivalent inhibitor of prostate-specific membrane antigen labeled with 67Cu
US20250340519A1 (en) Radiolabelled compound
Rogers et al. MicroPET imaging of gene transfer with a somatostatin receptor–based reporter gene and 94mTc-demotate 1
Schmitt et al. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model
CN114404618A (zh) 放射性药物水溶液及其用途
Kersemans et al. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences